A Study of DS-7011a in Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Systemic lupus erythematosus (SLE) is a systemic chronic autoimmune disease characterized by
autoantibody production, inflammation, and tissue damage in multiple organs. Standard of care
therapies used to treat SLE are only partially effective and have a wide range of toxicities.
There is a need for more effective and safer therapies for patients with SLE.